BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36401483)

  • 21. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Large cell neuroendocrine carcinoma of the ovary.
    Lindboe CF
    APMIS; 2007 Feb; 115(2):169-76. PubMed ID: 17295684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
    Eba J; Kenmotsu H; Tsuboi M; Niho S; Katayama H; Shibata T; Watanabe S; Yamamoto N; Tamura T; Asamura H; ;
    Jpn J Clin Oncol; 2014 Apr; 44(4):379-82. PubMed ID: 24474818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Small cell neuroendocrine carcinoma of the urinary bladder: a case report].
    Iwamura H; Horii Y; Arai E
    Hinyokika Kiyo; 1999 Sep; 45(9):641-4. PubMed ID: 10540713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
    Hainsworth JD; Spigel DR; Litchy S; Greco FA
    J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review and two new cases of primary upper urinary tract neuroendocrine carcinomas.
    Nakasato T; Hiramatsu A; Matsui Y; Unoki T; Shimoyama H; Oshinomi K; Morita J; Maeda Y; Naoe M; Fuji K; Ogura H; Homma M; Yamochi T; Takimoto M; Ogawa Y
    Cancer Treat Res Commun; 2018; 17():23-30. PubMed ID: 30326420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy.
    Yamazaki S; Sekine I; Matsuno Y; Takei H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T; Kodama T; Asamura H; Tsuchiya R; Saijo N
    Lung Cancer; 2005 Aug; 49(2):217-23. PubMed ID: 16022916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
    Oh IJ; Kim KS; Park CK; Kim YC; Lee KH; Jeong JH; Kim SY; Lee JE; Shin KC; Jang TW; Lee HK; Lee KY; Lee SY
    BMC Cancer; 2016 Aug; 16(1):690. PubMed ID: 27566413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poor prognosis of ovarian cancer with large cell neuroendocrine carcinoma: case report and review of published works.
    Asada K; Kawana K; Teshima S; Saito A; Kawabata M; Fujii T
    J Obstet Gynaecol Res; 2014 Mar; 40(3):869-72. PubMed ID: 24738132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer.
    Binder PS; Hashim YM; Cripe J; Buchanan T; Zamorano A; Vangveravong S; Mutch DG; Hawkins WG; Powell MA; Spitzer D
    BMC Cancer; 2022 Mar; 22(1):263. PubMed ID: 35279106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
    Cho HY; Kim YB; Park WH; No JH
    Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Large cell neuroendocrine carcinoma of the endometrium: A case report and literature review.
    Tu YA; Chen YL; Lin MC; Chen CA; Cheng WF
    Taiwan J Obstet Gynecol; 2018 Feb; 57(1):144-149. PubMed ID: 29458887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neuroendocrine small-cell bladder cancer: our experience].
    Ruoppolo M; Pezzica E; Milesi R; Corti D; Mercurio P; Fragapane G
    Urologia; 2010; 77 Suppl 17():64-71. PubMed ID: 21308678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term survival of a patient with primary small cell neuroendocrine carcinoma of the maxillary sinus: a case report.
    Hosokawa S; Okamura J; Takizawa Y; Mineta H
    J Oral Maxillofac Surg; 2013 Aug; 71(8):e248-52. PubMed ID: 23866955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.
    Fazio N; Spada F; Giovannini M
    Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.
    Zhang P; Li J; Li J; Zhang X; Zhou J; Wang X; Peng Z; Shen L; Lu M
    Cancer; 2020 May; 126 Suppl 9(Suppl 9):2086-2092. PubMed ID: 32293725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
    Le Treut J; Sault MC; Lena H; Souquet PJ; Vergnenegre A; Le Caer H; Berard H; Boffa S; Monnet I; Damotte D; Chouaid C
    Ann Oncol; 2013 Jun; 24(6):1548-52. PubMed ID: 23406729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
    Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW
    Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Small cell neuroendocrine carcinoma of the bladder. A new case report].
    Ghadouane M; Zannoud M; Alami M; Albouzidi A; Labraimi A; Safi L; Abbar M
    Ann Urol (Paris); 2003 Apr; 37(2):75-8. PubMed ID: 12741197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.